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Human pancreas organoids are a promising cell therapy candidate for Type I Diabetes Mellitus (T1DM). T1DM 
is a disabling chronic disease with a juvenile onset. Auto-immune destruction of pancreatic beta cells results in 
insufficient insulin production to manage blood glucose. This can lead, on the long-term, to serious 
complications, such as hypoglycemic episodes, neuropathy, retinopathy, and renal failure. The current standard 
of care is insulin therapy. However this cannot fully prevent long-term complications from arising, especially in 
patients suffering from uncontrolled T1DM with severe hypoglycemic episodes. Restoration of the natural blood 
glucose management can prevent complications, for instance by restoring the beta cell population with a cell 
therapy. Organoids, proclaimed by the journal Nature as “Method of the year 2017”, are 3D structures that can 
be generated from progenitor cells of many different organs, such as pancreas, liver, brain, lung, and heart. 
These miniature organs, when differentiated to produce insulin, can be a 3D cell therapy for T1DM. In case of 
the pancreas, these can be generated from adult-derived progenitor cells, which have a safer profile than ESC 
or iPSC based cell therapies for T1DM. 
 
Lonza Netherlands is a partner within the LSFM4LIFE project: a European consortium of universities and 
industrial partners that aims to produce a GMP batch of human pancreas organoids. To reach this goal, two 
milestones need to be achieved. First, to transfer the research process of organoid production into GMP. 
Specific challenges are a scalable GMP compliant platform for 3D culture and replacing research materials (e.g. 
complex media formulations and culture substrates) with GMP compliant substitutes. Additionally in process 
controls and QC assays are in its infancy for organoids and need to be developed. The second milestone is to 
develop a strategy for commercialization of this therapy, for which a number of analyses have been performed. 
A market and SWOT analysis have been performed (Figure 1). A clinical strategy is proposed to first access the 
market with an introduction into a small patient cohort and then to stay on the market by reaching all T1DM 
patients. An assessment of the manufacturing cost of goods is made for the current process, as well as how it 
could be envisioned in a commercial setting. From these costs, the cost-effectiveness compared to insulin 
therapy and islet of Langerhans transplantation is evaluated [1]. In conclusion, while the potential for organoids 
as a cellular therapy is considerable, this paper addresses the progress so far and the major challenges ahead.  
 
The unique aspect of this paper is that it 
describes the commercialization of an early 
stage 3D cell therapy. Organoids could be 
envisioned as an autologous ex vivo gene 
therapy for a subset of T1DM patients, or a 
donor-matched allogeneic treatment, but 
could finally be used as an allogeneic 
treatment. Additionally, the assessments on 
this therapy are applicable in a broader sense 
to other therapeutic areas of organoids and to 
other 3D cell therapies. For some cell therapy 
applications, 3D structures could be essential 
to their success (e.g. cardiovascular, organ 
function replacement) and could be the next 
generation of cell therapies.  
 
The paper is relevant for the sections 
“Advances in cell processing: New 
Techniques for new therapies” and potentially 
for “Bioprocess modeling for successful 
commercialization of advanced therapies” 




No immunosuppression drugs  
Gene editing and viral vectors 
possible  
No competitor yet active in 
late clinical or commercial 
Threats 
No clear cost/benefit plan 
Genetically engineered 
insulin secreting cell line 
available 
Crowded market in 
development / early clinical 
Weaknesses 
Differentiation only 
established in mouse  
Large scale production is 
challenging 





Expected safer compared to 
IPSCs and ESCs 
Less/no donor limitations 
compared to islets 
 
Figure 1 – Strengths Weaknesses Opportunities Threats 
(SWOT) analysis on pancreas organoid cell therapy. 
